{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:31:03Z","timestamp":1775287863466,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1016\/s0920-1211(01)00231-5","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T17:15:05Z","timestamp":1027617305000},"page":"197-206","source":"Crossref","is-referenced-by-count":85,"title":["Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine"],"prefix":"10.1016","volume":"44","author":[{"given":"Dominik","family":"Hainzl","sequence":"first","affiliation":[]},{"given":"Ant\u00f3nio","family":"Parada","sequence":"additional","affiliation":[]},{"given":"Patr\u0131\u0301cio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0920-1211(01)00231-5_BIB1","series-title":"Advances in Epileptology \u2014 1977","first-page":"295","article-title":"Experimental anticonvulsive properties of GP47680 and of 47779, its main human metabolite; compounds related to carbamazepine","author":"Baltzer","year":"1978"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB4","series-title":"Side Effects of Drugs","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0378-6080(88)80072-2","article-title":"Anticonvulsant drugs","author":"Davies-Jones","year":"1988"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB5","series-title":"Advances in Epileptology \u2014 1977","first-page":"290","article-title":"Pharmacokinetics and metabolism of GP 47 680, a compound related to carbamazepine, in animals and man","author":"Feldmann","year":"1978"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB6","series-title":"Advances in Epileptology: XIIth Epilepsy Int. Symp.","first-page":"89","article-title":"Pharmacokinetics and metabolism of GP 47 779, the main human metabolite of oxcarbazepine (GP 47 680) in animals and healthy volunteers","author":"Feldmann","year":"1981"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/bmc.1130050507","article-title":"Solid phase extraction of oxcarbazepine and its metabolites from plasma for analysis by high performance liquid chromatography","volume":"5","author":"Hartley","year":"1991","journal-title":"Biomed. Chrom."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1528-1157.1980.tb04081.x","article-title":"Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects","volume":"21","author":"Hoppener","year":"1980","journal-title":"Epilepsia"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1987.tb03702.x","article-title":"Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?","volume":"28","author":"Houtkooper","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB10","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB12","series-title":"Antiepileptic Drugs","first-page":"515","article-title":"Carbamazepine: absorption, distribution, and excretion","author":"Morselli","year":"1995"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/WNL.33.7.904","article-title":"A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults","volume":"33","author":"Ramsay","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0163-7258(95)02014-4","article-title":"Adverse effects of established and new antiepileptic drugs: an attempted comparison","volume":"68","author":"Rogvi-Hansen","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/jnnp.50.7.829","article-title":"Incidence and prevalence studies in epilepsy and their methodological problems: a review","volume":"50","author":"Sander","year":"1987","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"key":"10.1016\/S0920-1211(01)00231-5_BIB17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazepine in man","volume":"16","author":"Sch\u00fctz","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/S0920-1211(01)00231-5_BIB18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0165-6147(94)90059-0","article-title":"Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings","volume":"15","author":"Upton","year":"1994","journal-title":"Trends Pharm. Sci."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121101002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121101002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T01:28:54Z","timestamp":1620523734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121101002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":18,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S0920121101002315"],"URL":"https:\/\/doi.org\/10.1016\/s0920-1211(01)00231-5","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}